Navigation Links
ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
Date:1/7/2011

terms and conditions that are materially different from the terms described in this press release; the risk that ADVENTRX may not be able to integrate the target company successfully into its operations or that it may incur unexpected costs and disruptions to its business as a result of such integration; the potential for the FDA to require ADVENTRX to perform additional nonclinical, or clinical studies prior to initiating or following completion of the currently contemplated phase 3 clinical trial of the TPC for the treatment of sickle cell crisis; the risk that subsequent nonclinical or clinical study results do not support the safety and efficacy or the commercial viability of the TPC or any other product candidate developed using technology acquired from the target company; the risk that the neither the FDA nor any other regulatory agency approves a product based on the TPC or any other product candidate developed using technology acquired from the target company on a timely basis, or at all; the potential for the out-of-pocket cost to ADVENTRX and the time required for development of the TPC necessary to support an NDA submission are greater than ADVENTRX's current expectations; the risk that the TPC loses its orphan drug designation for the treatment of sickle cell crisis or that a third party's product candidate is shown to be clinically superior and is approved by the FDA during the TPC's market exclusivity period; the risk that individuals previously involved in the development of the TPC will not assist ADVENTRX in further development of the TPC and that ADVENTRX may be unable to retain the services of other qualified individuals on a timely basis, or at all; ADVENTRX's planned reliance on third parties to assist with its nonclinical and clinical studies, regulatory submissions, manufacturing and other important aspects of the TPC development program, if it consummates a transaction with the target company, and the risk that FDA approval may be delayed if
'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... /PRNewswire-iReach/ -- Dan York has been named ... the RTD ® Advanced Wound Care Dressing, as ... presence in the U.S. Under York,s leadership, GWM Products, ... sales representatives in new sales territories that will complement ... up to 20 sales representatives in major metropolitan areas ...
(Date:9/16/2014)... Sept. 16, 2014 Adaptive Biotechnologies, a clinical ... to profile the adaptive immune system, is pleased to ... Chief Commercial Officer (CCO). The addition of Brain to ... hires from leading global healthcare companies, including Dean ... Counsel) from Genomic Health and Sean Nolan ...
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
Breaking Medicine Technology:GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4
... 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... present at the Sixth Annual JMP Securities Healthcare Conference on ... a.m. Pacific Time) at The St. Regis New York Hotel ... Executive Officer, is scheduled to provide a corporate overview. ...
... MINNEAPOLIS, Sept. 21, 2011 Uroplasty, Inc. (NASDAQ: ... markets innovative proprietary products to treat voiding dysfunctions, announced today ... President and CFO, will present the Company,s business strategy and ... at 2:30 PM ET on Tuesday, September 27, 2011 at ...
Cached Medicine Technology:Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference 2Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference 3Uroplasty to Present at the 6th Annual JMP Securities Healthcare Conference 2
(Date:9/16/2014)... HORAN, a leading advisor in employee benefits ... as Vice President – Retirement Services. , Paul works ... planning. In addition, he monitors investments, fees and providers ... has been a retirement services industry professional for over ... a Senior Investigator at the Department of Labor facilitates ...
(Date:9/16/2014)... 16, 2014 Since the adoption of ... risen considerably in line with increased investment in R&D ... labels include novel paediatric information and more than 130 ... European countries, there has been 221 changes relating to ... submission of old or new trials in children and ...
(Date:9/16/2014)... 2014 This month’s issue features a ... newly elected chairman, Robert Vail of Vail Automotive in ... further the causes of the state’s franchised new car ... the retail automotive industry’s top names including Jenn Reid ... important to take a “360 view” of the customer ...
(Date:9/16/2014)... 2014 LiveOps, the global leader ... announced today that the company has received a ... the creation of a social learning ecosystem and ... Group honors companies that have successfully developed and ... that have helped companies achieve measurable results. This ...
(Date:9/16/2014)... Hudson County, NJ (PRWEB) September 16, 2014 ... that a leading Bariatric Surgeon, Leigh Montes, MD, ... of Bariatric Surgery at Christ Hospital. Our system ... Bariatric Center, a medical and surgical weight loss ... through the most advanced bariatric surgery procedures, including ...
Breaking Medicine News(10 mins):Health News:Paul Carl Joins HORAN's Retirement Plan Consulting Organization 2Health News:Paediatric Drug Development Market Analysed by CBR Pharma Insights in In-demand Report Available at MarketPublishers.com 2Health News:Paediatric Drug Development Market Analysed by CBR Pharma Insights in In-demand Report Available at MarketPublishers.com 3Health News:September Issue of Car Biz Today Magazine Available Online 2Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 2Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 3Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 4Health News:Top Bariatric Surgeon Joins CarePoint Health 2Health News:Top Bariatric Surgeon Joins CarePoint Health 3
... When the Spanish capital Madrid decided to replace the thin ... the kind of move that millions of women// around the ... measures to ban very skinny fashion models and to promote ... international interest, a spokesman for the regional government says. ...
... recent research shows that the translaminar approach to cervical ... percent of those treated. ,In addition ... found to be safer than an alternative method or ... alternative approach, steroids are injected in close proximity to ...
... kick the butt. There will be no escape into outdoor areas ... bill// of British Columbia hits the public. ,The new ... in all indoor public spaces as well as in public doorways, ... accessible by the public. , Says Health Minister George ...
... it comes to health care for our kids, we live ... tougher. That is the underlying message// from three University of ... complete overhaul of the U.S child health care system. ... issue of the journal Health Affairs, Dr. Neal Halfon, director ...
... found two of three newer antipsychotic drugs are more ... older medication, according to a research. ,The ... longstanding Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE). Dr. ... School of Medicine, is the lead author. ...
... specialists have underlined the urgency to uplift end of life care. ... the flaws// in the healthcare system that do not adequately ... ,Our health care systems do not reliably meet the needs of ... write Sydney Dy and Joanne Lynn, two palliative care doctors based ...
Cached Medicine News:Health News:Spain Launches Movement Against Skinny Fashion Models 2Health News:Spain Launches Movement Against Skinny Fashion Models 3Health News:Neck Pain Treatment Safer Without Significant Risk of Paralysis 2Health News:U.S. Child Health System Needs Total Overhaul 2Health News:Study Sheds Light on Value of Newer Antipsychotic Drugs for Schizophrenia 2Health News:Care During Last Phase of Life Needs to Be Uplifted 2
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
Inquire...
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Rapid latex slide agglutination assay for the qualitative and semi-quantitative determination of Rheumatoid Factors in human serum....
Medicine Products: